January 24, 2012 European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the
January 12, 2011 Patient Self-report for Evaluating Mild Cognitive Impairment and Prodromal Alzheimer’s Disease
November 3, 2011 Capturing the Signal in Mild Cognitive Impairment of the Alzheimer’s Type: Industry Partnerships in Pre-Competitive Measure Development
November 2, 2011 C-Path Joins Leading Voices and Organizations in Alzheimer’s Research, Drug Discovery and Care to Call for Dramatic New Strategy to Stop Alzheimer’s Disease in Report Out Today Leaders Engaged on Alzheimer’s Disease (LEAD) was created in February 2008 as an open network of Alzheimer’s-serving o
October 18, 2011 Critical Path Institute and Clinical Data Interchange Standards Consortium Announce Release of Data Standards for Alzheimer’s Disease Research Critical Path Institute(C-Path)and Clinical Data Interchange Standards Consortium(CDISC) today announced the release of version 1.
October 2, 2011 C-Path’s K. Romero Co-Authors Special Report- Striving for an Integrated Drug-Development Process for Neurodegeneration: the Coalition Against Major Diseases Alzheimer’s and Parkinson’s diseases are the two main neurodegenerative disorders and despite the public health need,
December 11, 2010 Executive director of Critical Path Institute’s Coalition Against Major Diseases testifies before congress on Alzheimer’s disease progress Marc Cantillon, MD, presents the critical role of public/private partnerships in creating innovative tools to advance the developm
November 11, 2010 Leading Neuroscientist Joins Critical Path Institute Marc Cantillon, MD, has joined Critical Path Institute as Executive Director of one of its major consortia, the Coalition Against
